Total Valuation
Hanall Biopharma Co., Ltd. has a market cap or net worth of ₩2.12T. The enterprise value is ₩2.82M.
Market Cap₩2.12T
Enterprise Value₩2.82M
Share Statistics
Hanall Biopharma Co., Ltd. has 52,240,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding52,240,640
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Hanall Biopharma Co., Ltd.’s return on equity (ROE) is -0.03 and return on invested capital (ROIC) is -0.74%.
Return on Equity (ROE)-0.03
Return on Assets (ROA)-0.02
Return on Invested Capital (ROIC)-0.74%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee492.65M
Profits Per Employee-17.65M
Employee Count315
Asset Turnover0.69
Inventory Turnover2.00
Valuation Ratios
The current PE Ratio of Hanall Biopharma Co., Ltd. is ―. Hanall Biopharma Co., Ltd.’s PEG ratio is -1.84.
PE Ratio―
PS Ratio14.05
PB Ratio13.48
Price to Fair Value13.48
Price to FCF-662.91
Price to Operating Cash Flow312.18
PEG Ratio-1.84
Income Statement
In the last 12 months, Hanall Biopharma Co., Ltd. had revenue of 155.18B and earned -5.56B in profits. Earnings per share was -111.55.
Revenue155.18B
Gross Profit79.10B
Operating Income-1.61B
Pretax Income-6.18B
Net Income-5.56B
EBITDA1.94B
Earnings Per Share (EPS)-111.55
Cash Flow
In the last 12 months, operating cash flow was 7.56B and capital expenditures -4.24B, giving a free cash flow of 3.32B billion.
Operating Cash Flow7.56B
Free Cash Flow3.32B
Free Cash Flow per Share63.54
Dividends & Yields
Hanall Biopharma Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change43.91%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)520.26K
Important Dates
Hanall Biopharma Co., Ltd. upcoming earnings date is Oct 22, 2026, TBA (Confirmed).
Last Earnings DateJul 29, 2026
Next Earnings DateOct 22, 2026
Ex-Dividend Date―
Financial Position
Hanall Biopharma Co., Ltd. as a current ratio of 1.91, with Debt / Equity ratio of 27.22%
Current Ratio1.91
Quick Ratio1.05
Debt to Market Cap0.01
Net Debt to EBITDA3.70
Interest Coverage Ratio-11.31
Taxes
In the past 12 months, Hanall Biopharma Co., Ltd. has paid -621.61M in taxes.
Income Tax-621.61M
Effective Tax Rate0.10
Enterprise Valuation
Hanall Biopharma Co., Ltd. EV to EBITDA ratio is 1.13K, with an EV/FCF ratio of -665.09.
EV to Sales14.09
EV to EBITDA1.13K
EV to Free Cash Flow-665.09
EV to Operating Cash Flow-934.50
Balance Sheet
Hanall Biopharma Co., Ltd. has ₩36.16B in cash and marketable securities with ₩44.20B in debt, giving a net cash position of -₩8.04B billion.
Cash & Marketable Securities₩36.16B
Total Debt₩44.20B
Net Cash-₩8.04B
Net Cash Per Share-₩153.87
Tangible Book Value Per Share₩1.95K
Margins
Gross margin is 51.65%, with operating margin of -1.04%, and net profit margin of -3.58%.
Gross Margin51.65%
Operating Margin-1.04%
Pretax Margin-3.98%
Net Profit Margin-3.58%
EBITDA Margin1.25%
EBIT Margin-1.04%
Analyst Forecast
The average price target for Hanall Biopharma Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast8.38%
EPS Growth Forecast-1190.78%